Bhaskar Dasgupta, ACR 2022: A validation study of the Southend pre-test probability score
The southend pre-test probability score (SPTPS) was recently developed to estimate the probability of giant cell arteritis (GCA) based on symptoms, signs and lab findings. In this interview with Prof. Bhaskar Dasgupta (Southend University Hospital NHS Foundation Trust, Southend-on-Sea, UK) we discuss the validation study of SPTPS and how effective the score was in assessing the clinical probability of GCA among suspected new cases.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract ‘Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study‘ (Abstract number: 1620) was presented at the ACR Convergence, November 10–14, 2022.
- Can you give us a brief overview of the Southend pre-test probability score (SPTPS)? (0:05)
- What was the methodology of your validation study of SPTPS? (1:55)
- How effective was the SPTPS in assessing the clinical probability of GCA among people with suspected new onset GCA? (5:44)
Disclosures: Bhaskar Dasgupta discloses consulting for Sanofi; receiving grant/ research support from Sanofi; and receiving honoraria from Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of the ACR Convergence 2022.
Share this Video
Related Videos In Vasculitis
Naomi J Patel, ACR 2022: Impact of tocilizumab on HbA1C during giant cell arteritis treatment
GiACTA was a randomized, double-blind, placebo-controlled study that investigated the safety and efficacy of tocilizumab, an IL-6 receptor antagonist, in patients with giant cell arteritis. touchIMMUNOLOGY were delighted to speak with Dr. Naomi J Patel (Massachusetts General Hospital, Boston, MA, USA) to discuss the aims, design and findings from her post-hoc analysis of the GiACTA […]
Robert Spiera, ACR 2022: Sarilumab for glucocorticoid resistant polymyalgia rheumatica – the SAPHYR study
The SAPHYR study (NCT03600818) investigated sarilumab, a fully human anti–IL-6Rα monoclonal antibody, in patients with glucocorticoid resistant polymyalgia rheumatica (PMR), measuring efficacy by sustained remission in PMR. touchIMMUNOLOGY were delighted to speak with Dr. Robert Spiera (Weill Cornell Medical College, New York, NY, USA) around the aims, design, inclusion criteria and findings from the SAPHYR […]
Lisa Christ, ACR 2022: Tocilizumab and ultra-short glucocorticoids in giant cell arteritis – one year follow-up of GUSTO
The GUSTO trial (NCT03745586) investigated the efficacy and safety of tocilizumab (TCZ )-monotherapy after ultra-short glucocorticoid treatment in new-onset giant cell arteritis (GCA). touchIMMUNOLOGY caught up with Dr. Lisa Christ (University of Bern, Inselspital, Bern, Switzerland) to discuss this analysis of GUSTO exploring the maintenance of remission 1 year after discontinuation of TCZ treatment. This […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!